Literature DB >> 10699920

Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis.

M Takata1, R Morita, K Takehara.   

Abstract

The major obstacle preventing effective treatment of melanoma is the biological heterogeneity of tumor cells. This study was performed to determine clonal genetic heterogeneity within primary melanoma and the evolution of these heterogeneous sub-clones during disease progression. DNA samples were obtained from 44 morphologically distinct areas identified within 10 primary tumors and from 15 metastases in the same patients. Loss of heterozygosity (LOH) analyses were performed using 17 microsatellite markers that mapped to chromosomes 6q, 9p, 10q and 18q, the most frequently deleted in melanoma. Of 10 primary tumors, 8 were revealed to have intratumoral genetic heterogeneity in terms of LOH of the 4 chromosome arms examined, 7 containing at least 2 different sub-clones harboring LOH of different chromosome areas, while the remaining one tumor showed prominent intratumoral genetic heterogeneity consisting of at least 6 genetically distinct sub-clones. LOH of 6q was detected only in a sub-set of multiple microdissected samples in most of the primary tumors, but was most frequently detected in metastases, suggesting that loss of this chromosome arm occurred late and played an important part in metastatic progression. Comparison of LOH between sub-clones within primary tumors and within metastases showed the divergence of metastatic clones from dominant populations within the primary tumor in 5 patients, whereas in the remaining three patients parent sub-clones were not identified, or constituted only a minor sub-population within the primary tumors. These results, showing considerable genetic heterogeneity in sporadic melanoma, have profound implications for the choice of future therapeutic strategies. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10699920

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.

Authors:  Carmen Ruiz; Julia Li; Madelyn S Luttgen; Anand Kolatkar; Jude T Kendall; Edna Flores; Zheng Topp; Wolfram E Samlowski; Edward McClay; Kelly Bethel; Soldano Ferrone; James Hicks; Peter Kuhn
Journal:  Phys Biol       Date:  2015-01-09       Impact factor: 2.583

2.  [DNA copy number changes in the diagnosis of melanocytic tumors].

Authors:  J Bauer; B C Bastian
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

Review 3.  Progress in understanding melanoma propagation.

Authors:  Mark Shackleton; Elsa Quintana
Journal:  Mol Oncol       Date:  2010-06-23       Impact factor: 6.603

Review 4.  Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.

Authors:  Nicholas A Saunders; Fiona Simpson; Erik W Thompson; Michelle M Hill; Liliana Endo-Munoz; Graham Leggatt; Rodney F Minchin; Alexander Guminski
Journal:  EMBO Mol Med       Date:  2012-06-25       Impact factor: 12.137

Review 5.  The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth.

Authors:  Patrick Schmidt; Hinrich Abken
Journal:  Oncotarget       Date:  2011-04

6.  Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors.

Authors:  Matthew Anaka; Christopher Hudson; Pu-Han Lo; Hongdo Do; Otavia L Caballero; Ian D Davis; Alexander Dobrovic; Jonathan Cebon; Andreas Behren
Journal:  BMC Med Genomics       Date:  2013-10-11       Impact factor: 3.063

7.  Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

Authors:  Alexander M Menzies; Lauren E Haydu; Matteo S Carlino; Mary W F Azer; Peter J A Carr; Richard F Kefford; Georgina V Long
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

8.  Targeted alternative splicing of TAF4: a new strategy for cell reprogramming.

Authors:  Jekaterina Kazantseva; Helle Sadam; Toomas Neuman; Kaia Palm
Journal:  Sci Rep       Date:  2016-08-08       Impact factor: 4.379

9.  Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.

Authors:  Marieke I G Raaijmakers; Daniel S Widmer; Apurva Narechania; Ossia Eichhoff; Sandra N Freiberger; Judith Wenzina; Phil F Cheng; Daniela Mihic-Probst; Rob Desalle; Reinhard Dummer; Mitchell P Levesque
Journal:  Oncotarget       Date:  2016-11-22

Review 10.  Intratumor and Intertumor Heterogeneity in Melanoma.

Authors:  Tomasz M Grzywa; Wiktor Paskal; Paweł K Włodarski
Journal:  Transl Oncol       Date:  2017-10-24       Impact factor: 4.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.